EVERSANA’s Post

Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/gqBrzcKT #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox

#ASCO2024 starts today and we’re looking forward to putting our new learnings into practice. A common theme we continue to see in the industry is that biopharma companies struggle with effectively reaching the oncologists with the greatest impact on patient care in the community setting. That's where we come in! In a recent 81qd study within oncology, our purpose-built healthcare data analytics software Plexus found that 70% of Clinical Leaders identified were community-based oncologists. Clinical Leaders are the most connected clinicians based on real-world patterns of patient flow. ASCO is the perfect opportunity to put our insights into action and connect with the community. If you’re attending this year’s event, we hope to see you there! #81qd #ASCO #biopharma #oncology #dataanalytics #artificialintelligence

Join us this Wednesday! Learn the #RTSM factors #Oncology trial sponsors should consider in #IRT design and how Calyx accommodates changes in centrally/locally sourced medication for optimal #clinicaltrial supply management. Register now. https://lnkd.in/gswrJfdS #TrialSupplyManagement #Randomization #ChooseCalyx Peter Tarbox

Did you know that 57% of protocols across all trial phases face at least one substantial global amendment; the cost of which ranges up to $535,000? As life sciences companies face significant risk to the smooth progress of their trials, discover how IQVIA Biotech helped one sponsor avoid substantial amendment through data-informed protocol assessment. Find the case study on page 24 of the report: Improving Decision-Making through Connected Intelligence. https://bit.ly/4bToRgJ #clinicaltrials #drugdevelopment #oncology

Discover an eCOA/ePRO platform that is customizable for your oncology trial’s unique challenges. Datacubed Health offers cycle-based management that aligns with the non-linear nature of oncology studies, enhancing patient engagement while streamlining your workflow. Visit our website to dive deeper into this purpose-built solution. https://lnkd.in/gy454Xe2 #eCOA #oncologytrials #oncologyresearch 

Site performance isn’t just a number; it’s a story waiting to be told. With Teckro’s Site Performance Quadrant, you can uncover the narrative behind each site’s engagement. By pairing recruitment metrics with these insights, you’ll understand where to focus your efforts. It’s about crafting a more successful trial experience for everyone involved 👇👇👇

Positive top line results from ARANOTE are here. 🚨 “Darolutamide plus ADT now has positive data both with and without docetaxel..”

Accelerated approvals, staying abreast of rapid changes in data and navigating regulatory intricacies further complicate the commercialization process for #oncology therapies. Consequently, challenges such as infrastructure, risk spend and communicating value emerge as significant challenges. In their latest article, EVERSANA’s experts provide considerations and innovative approaches for brands to enhance their commercialization strategies. Read now: https://ow.ly/4emF50QRnV0

🔍 How can real-time patient data transform clinical trials? By making trials more adaptable, efficient and customized for better outcomes. Discover how leveraging data is reshaping clinical research and driving faster results—especially in complex areas like oncology. 📊 Read our PharmaTimes Media Ltd article by Samantha Morley and Domantas Gurevicius now to learn more: https://hubs.la/Q02RWYlv0 #ClinicalResearch #DataDriven #OncologyTrials #PrecisionMedicine #PatientOutcomes #ClinicalTrials

Check out Kyle Hogan talk to our oncology captabilties!